Loading...
Loading...
NCNA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,323.0K |
| Operating I/L | -5,323.0K |
| Other Income/Expense | 72.0K |
| Interest Income | 72.0K |
| Pretax | -5,251.0K |
| Income Tax Expense | -740.0K |
| Net Income/Loss | -4,511.0K |
NuCana plc is a clinical-stage biopharmaceutical company specializing in the development of cancer treatment products. The company's lead product candidate, Acelarin, is undergoing various clinical trials for the treatment of advanced solid tumors, recurrent ovarian cancer, biliary tract cancer, platinum-resistant ovarian cancer, and pancreatic cancer. Additionally, NuCana is developing NUC-3373 and NUC-7738, both in Phase I/II clinical trials for the treatment of advanced solid tumors, hematological tumors, and colorectal cancer. The company's revenue is generated through the development and potential commercialization of its proprietary ProTide technology-based products for cancer treatment.
